Journal Article

Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace® balloon, in patients treated with radiotherapy for prostate cancer

Labarthe, P., Seguin, P., Tollon, C., Bruguière, E., Latorzeff, I., Guillotreau, J., Dudouet, P., Janoray, G., Mazurier, J.

2024

Overview

A bstract Background Due to the close proximity of the prostate and rectum, rectal toxicity remains a major problem in patient treated by radiotherapy for prostate adenocarcinoma. One method of increasing the distance between the prostate and the rectum is to use a spacer implanted into the rectoprostatic space. This report describes the long-term outcomes obtained with a new ballon spacer. Methods Patients treated with curative radiotherapy for low- or intermediate-risk prostate adenocarcinoma, who underwent insertion of the ProSpace® (BioProtect Ltd, Tzur Yigal, Israel) rectal-prostate balloon spacer, were included. The main objective was to evaluate the dosimetric benefit of the spacer for OARs. The secondary objectives were to evaluate the feasibility and tolerability of ProSpace® balloon placement and to evaluate its long-term therapeutic efficacy and tolerance. Results Between October 2013 and March 2015, 16 patients were enrolled in the Pasteur Clinic, Toulouse, France. The median follow-up was 85.5 months. From top to bottom, the space created was a mean of 16.3 mm (range: 11–20.5 mm) at the base of the prostate, 12.1 mm (range: 4–16 mm) at the middle and 8.9 mm at the apex (range: 5–15 mm). On average, rectal volumes receiving a dose of 70 Gy, 60 Gy and 50 Gy were significantly lower after balloon implantation: -4.81 cc (1.5 vs. 6.3; p  < 0.0005), -8.08 cc (6.4 vs. 14.5; p  = 0.002) and -9.06 cc (16.7 vs. 25.7; p  = 0.003), respectively. There were significant differences in coverage after balloon implantation: Median V95% ( p  < 0.0005), median Dmin ( p  = 0.01) and median V98% ( p  < 0.001) were higher after balloon implantation. At 5 years, cumulative gastrointestinal toxicity was grade 1 in 6% (1/16 patients). No toxicity of grade 2 or higher was found. At 5 years, no urinary toxicity grade 3 or 4 toxicity was found. The QoL was not deteriorated. Conclusions The use of the ProSpace® balloon seems to be well accepted by patients, allowing a double dosimetric gain: a decrease in doses received by the rectum and an improvement in the coverage of the high-risk PTV. The long-term gastrointestinal toxicity remains low and QoL is preserved in all treated patients.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adenocarcinoma / Adenocarcinoma - radiotherapy / Aged / Aged, 80 and over / Ballon / Balloon treatment / Biomedical and Life Sciences / Biomedicine / Bladder / Cancer Research / Care and treatment / Diagnosis / Dosimetric gain / Dosimetry / Follow-Up Studies / Health aspects / Health Promotion and Disease Prevention / Humans / Lymphatic system / Magnetic resonance imaging / Male / Medical equipment / Medicine/Public Health / Middle Aged / Oncology / Patient outcomes / Patients / Prostate - pathology / Prostate - radiation effects / Prostate cancer / Prostatic Neoplasms - radiotherapy / Quality of life / Questionnaires / Radiation Injuries - etiology / Radiation Injuries - prevention & control / Radiation therapy / Radiotherapy / Radiotherapy Dosage / Rectoprostatic space / Rectum / Rectum - radiation effects / Safety and security measures / Surgical Oncology / Toxicity / Treatment Outcome